Scrip
US FDA examining reports of liver damage with orlistat
21 May 2009
Sue Sutter
Please Login to read the full article.
21 May 2009
Sue Sutter
The US FDA is investigating postmarketing reports of hepatotoxicity with the anti-obesity agent orlistat, the active ingredient in Roche's prescription drug Xenical and GlaxoSmithKline's over-the-counter version Alli.
The FDA's drug safety oversight board, which meets in private and is...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
